mRNA-4157,Pembrolizumab
Moderna,Merck
['melanoma']
exciting data from #asco23 on personalized #cancer #vaccines in #melanoma. caution is however needed, short follow up (&gt;80 weeks landmark with less than 29 pts at risk in the control group), graphs below 
Clinician-Scientist @CCITdk, Assoc. Prof. @uni_copenhagen interest in #immunotherapy #melanoma #RWE #TIL @myESMO communicationcommittee. drawing: David Shaholli